Neoadjuvant Therapy for Cancer of the Esophagus

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Esophageal cancer treatment traditionally relies on surgical resection, yet survival rates remain suboptimal.
• Inoperable cases utilize radiation and chemotherapy, prompting their investigation in the neoadjuvant setting for improved outcomes.
• Neoadjuvant therapies aim to enhance palliation and extend survival in esophageal cancer patients.

Purpose of the Study:

• To review existing literature on neoadjuvant chemotherapy and radiation therapy for esophageal cancer.
• To evaluate the efficacy of neoadjuvant treatments in squamous cell carcinoma and adenocarcinoma of the esophagus.

Main Methods:

• Literature review of clinical trials involving neoadjuvant chemotherapy and radiation therapy.
• Analysis of data concerning treatment outcomes for esophageal cancer.

Main Results:

• Surgery alone is frequently noncurative for esophageal cancer, even with curative intent.
• Most neoadjuvant therapy trials lack the statistical power to confirm clinically significant improvements.
• Preoperative radiation therapy alone shows insufficient evidence of benefit.
• Preoperative chemotherapy (5-FU plus cisplatin) followed by surgery offers minimal to no advantage over surgery alone.
• Combined preoperative chemoradiation therapy presents promising but inconclusive findings.

Conclusions:

• Neoadjuvant therapy for esophageal cancer should be limited to select patients within clinical trials.
• Future research is needed to establish the role of neoadjuvant chemoradiation and identify optimal patient populations and agents.